0.00Open0.00Pre Close0 Volume0 Open Interest17.50Strike Price0.00Turnover387.30%IV-364.19%PremiumMay 16, 2025Expiry Date13.73Intrinsic Value100Multiplier13DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9648Delta0.0342Gamma0.27Leverage Ratio-0.0067Theta-0.0026Rho-0.26Eff Leverage0.0005Vega
Pulmonx Stock Discussion
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
Pulmonx (Nasdaq: LUNG) presented clinical data from two significant studies at the European Respiratory Society Congress 2024. The AeriSeal® CONVERT trial showed that 77.6% of patients with collateral ventilation (CV+) successfully converted to CV- status after treatment with the AeriSeal System...
No comment yet